Brief: Tempest Therapeutics- Positive Early Results From Global Randomized Phase 1B/2 Combination Study Of Tpst-1120 In First-Line Hepatocellular Carcinoma
28/04/2023 14:09
Tempest Therapeutics Inc TPST.O :
* TEMPEST THERAPEUTICS- POSITIVE EARLY RESULTS FROM GLOBAL
RANDOMIZED PHASE 1B/2 COMBINATION STUDY OF TPST-1120 IN
FIRST-LINE HEPATOCELLULAR CARCINOMA
* TEMPEST THERAPEUTICS INC - ADDITION OF TPST-1120 RESULTED
IN A
CLINICALLY-MEANINGFUL IMPROVEMENT IN BOTH CONFIRMED AND
UNCONFIRMED RECIST RESPONSES
Source text for Eikon: ID:nGNX4qVKsc
Further company coverage: TPST.O
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T